Azenta (AZTA) stock plummeted 5.66% in pre-market trading on Wednesday following the release of its second-quarter financial results for fiscal year 2025. The life sciences company's earnings fell short of analyst expectations, despite reporting better-than-expected revenue.
For the quarter ended March 31, 2025, Azenta reported adjusted earnings per share (EPS) of $0.05, missing the analyst consensus estimate of $0.07 by 28.57%. This figure remained unchanged from the same period last year. However, the company's quarterly revenue came in at $143 million, surpassing the analyst consensus estimate of $140.91 million by 1.48%. Despite the revenue beat, this represents a 10.14% decrease compared to sales of $159.13 million in the same quarter last year.
The company's financial performance was mixed, with an operating loss of $16 million for the quarter. The adjusted EBITDA margin stood at 10%, while the gross margin improved to 45.9%, up 140 basis points year-over-year. Azenta reiterated its revenue guidance from continuing operations for the fiscal year 2025, maintaining a cautious outlook amid evolving market conditions. The market's negative reaction suggests investors were particularly concerned about the earnings miss and the year-over-year revenue decline, overshadowing the slight beat on top-line expectations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.